Accessibility Menu
Q32 Bio logo

Q32 Bio(NASDAQ) QTTB

Market Cap$466.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-6%
5 Year-86%
1 Year+606%
1 Month+24%
$15.68
+0.77%
+0.12Today
After hours$15.61-$0.07 (-0.45%)
Q32 Bio last closing stock price
MetricPriceDate
Last closeUSD 15.682026-07-31
Q32 Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.5%USD 15.152026-07-24
1 month+24.44%USD 12.602026-07-01
3 month+211.11%USD 5.042026-05-01
Year to date+372.29%USD 3.322025-12-31
1 year+606.31%USD 2.222025-07-31
3 year-39.08%USD 25.742023-08-01
5 year-86.3%USD 114.482021-07-30
Since inception-5.83%USD 16.652024-03-26

Q32 Bio Financials at a Glance

Market Cap

$466.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$53.74M

Net Income (TTM)

$33.24M

EPS (TTM)

$2.66

P/E Ratio

5.89

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$15.68

Volume

387,121.262

Open

$15.73

Previous Close

$15.68

Daily Range

$15.00 - $15.99

52-Week Range

$1.57 - $23.57

Estimated Earnings Date

Aug 5, 2026

QTTB News

Medical researchers - GettyImages-1096502340

Why Q32 Bio Stock Skyrocketed Today

Joe TenebrusoJul 13, 2026
Foolcom-Featured.png

Q32 Bio (QTTB) Q2 Loss Drops 45%

Motley Fool Markets TeamAug 6, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Q32 Bio

Q32 Bio develops medicines for people with immune system diseases. Its main products aim to help those with conditions like eczema or hair loss. These treatments work by calming overactive immune responses in the body.

Lab Bench to Bedside: Q32 Bio’s Main Offerings

  • Bempikibart (ADX-914): Antibody treatment in trials for eczema and hair loss; targets immune system overactivity. 0% of revenue in 2025.
  • ADX-097: Antibody fusion protein for kidney and immune diseases; Phase II trial discontinued in 2025. 0% of revenue in 2025.
  • ADX-096: Early-stage therapy for eye diseases linked to immune dysfunction; not yet in human trials. 0% of revenue in 2025.
  • Other C3d mAb fusions and nanobodies: Preclinical research for targeted immune therapies. 0% of revenue in 2025.

Plot Twists and Pivots: Growth & Expansion Moves

  • Completed a reverse merger with Homology Medicines in March 2024, adding $42M in financing.
  • Ended collaboration with Horizon Therapeutics (now part of Amgen), regaining full rights to bempikibart in 2023.
  • Restructured in February 2025 to focus on bempikibart for hair loss, cutting other programs and reducing staff.
  • Holds exclusive licenses from Bristol-Myers Squibb and the University of Colorado for certain core drug program patents and know-how, and non-exclusive licenses for other relevant patent families and know-how.

What Makes Q32 Bio Stand Out (Without the Lab Coat)

Q32 Bio focuses on targeted immune therapies, aiming for fewer side effects. Its main drug candidate blocks two immune signals, which may help more patients. The company’s small size allows it to shift focus quickly as research evolves.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024, down 100% from Q2 2023.
  • Net loss was $9.5 million in Q2 2025, improving 44.1% from Q2 2024.
  • Cash and equivalents were $54.8 million as of June 30, 2025, down 29.8% from December 2024.
  • Operating expenses fell to $9.2 million in Q2 2025, down 48.8% year-over-year.

Bottom Line

Q32 Bio has narrowed its focus to one main drug for immune-related hair loss. The company remains early-stage, with no product sales and ongoing financial challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

24

CEO

Jodie P. Morrison

Website

www.q32bio.com

Headquarters

Waltham, MA 02451, US

QTTB Financials

Key Financial Metrics (TTM)

Gross Margin

99.33%

Operating Margin

39.84%

Net Income Margin

61.86%

Return on Equity

230.68%

Return on Capital

29.47%

Return on Assets

52.21%

Earnings Yield

16.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$466.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

29.76M

Volume

387.12K

Avg. Volume

1.48M

Financials (TTM)

Gross Profit

$53.38M

Operating Income

$21.41M

EBITDA

$22.15M

Operating Cash Flow

-$27.40M

Capital Expenditure

$0.00

Free Cash Flow

-$27.40M

Cash & ST Invst.

$50.75M

Total Debt

$13.65M

Q32 Bio Performance Analysis

Q32 Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,208,000-90.6%
20232023-12-31USD -6,651,000N/A
20242024-12-31USD 0N/A
20252025-12-31USD 53,737,000N/A
Q32 Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Q32 Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.57-95.0%
20232023-12-31USD -153.979709.3%
20242024-12-31USD -6.58-95.7%
20252025-12-31USD 2.42N/A
Q32 Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3013.3%
Q32025-09-3023.1%
Q42025-12-31863.3%
Q12026-03-31-111.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$90.00K

+24.4%

Gross Margin

0.00%

N/A

Market Cap

$466.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$19.45M

N/A

Employees

24

N/A

Net Income

-$7.61M

+31.0%

EBITDA

-$7.63M

+28.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$50.75M

-22.5%

Total Debt

$13.65M

-27.4%

Accounts Receivable

$5.39M

+871.5%

Inventory

$0.00

N/A

Long Term Debt

$6.69M

-50.4%

Short Term Debt

$6.95M

+31.4%

Return on Assets

52.21%

N/A

Return on Invested Capital

40.39%

N/A

Free Cash Flow

-$6.34M

+49.2%

Operating Cash Flow

-$6.34M

+49.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANTXAN2 Therapeutics, Inc.
$5.35+0.38%
BOLDBoundless Bio, Inc.
$2.50+0.00%
VRCAVerrica Pharmaceuticals Inc.
$5.22-0.76%
GBIOGeneration Bio Co.
$5.34+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About QTTB

What is the current price of Q32 Bio?

Q32 Bio is trading at $15.68 per share.

What is the 52-week range for Q32 Bio?

Over the past 52 weeks, Q32 Bio has traded between $1.57 and $23.57.

How much debt does Q32 Bio have?

As of the most recent reporting period, Q32 Bio reported total debt of $13.65M.

How much cash does Q32 Bio have on hand?

Q32 Bio reported $50.75M in cash and cash equivalents in its most recent financial results.

What is Q32 Bio’s dividend yield?

Q32 Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services